Global Contrast Enhanced Mammography Market

Contrast Enhanced Mammography Market Size, Share, Growth Analysis, By Applications(Screening and Diagnosis), By End User(Hospital, Diagnostic Centres, Specialty Clinics, Others), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35G2123 | Region: Global | Published Date: July, 2024
Pages: 219 | Tables: 62 | Figures: 78

Contrast Enhanced Mammography Market Dynamics

Contrast Enhanced Mammography Market Drivers

  • The major factor driving the market growth is rising incidence of breast cancer. Breast cancer is the most common cancer among women worldwide. It is possible to treat breast cancer extremely effectively, especially if the disease is diagnosed early. A breast cancer patient is generally treated with surgery, radiation therapy, and medications (hormone therapy, chemotherapy, and/or targeted biological therapy) to treat the microscopic cancer that has spread from the breast tumor. Treatments such as these can prevent cancer growth and spread, thereby saving lives.
  • According to World Health Organization (WHO) 685 000 people worldwide died in 2020 as a result of breast cancer, which affected 2.3 million women. The most common cancer in the globe as of the end of 2020 was breast cancer, which had been diagnosed in 7.8 million women in the previous five years. Worldwide, breast cancer causes more lost disability-adjusted life years (DALYs) for women than any other type of cancer. Every country in the globe experiences breast cancer in women after puberty at any age, albeit the incidence rates rise as people age. Also, merely gender (female) and age, the only known risk factors for breast cancer in women, account for almost half of all cases (over 40 years). Ageing, obesity, drinking too much alcohol, radiation exposure history, family history of breast cancer, reproductive history (such as age at first pregnancy and age at first menstruation), smoking, and postmenopausal hormone therapy are some variables that raise the risk of breast cancer. However, even if all of the possibly controllable risk factors could be avoided, the risk of developing breast cancer would only be decreased by a maximum of 30%. Thus, increasing prevalence of breast cancer is increasing the demand for Contrast Enhanced Mammography, in turn driving the market.

Contrast Enhanced Mammography Market Restraints

  • Contrast-enhanced mammography is a relatively new technology, and its cost is higher than traditional mammography. The high cost of equipment, materials, and training needed for contrast-enhanced mammography can be a significant barrier to its adoption. Also, Contrast-enhanced mammography is not widely available, and the number of facilities that offer this technology is still limited. This can make it challenging for patients to access this type of imaging, particularly in rural or remote areas. Moreover, regulatory approval is required before contrast-enhanced mammography can be used in clinical practice. This approval process can be lengthy and expensive, and may delay the introduction of this technology to the market. In addition, although contrast-enhanced mammography has shown promising results in clinical studies, there is still a lack of long-term data on its effectiveness and safety. This can make some healthcare providers hesitant to adopt this technology until more evidence is available.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Contrast Enhanced Mammography market size was valued at USD 1.84 billion in 2022 and is poised to grow from USD 1.94 billion in 2023 to USD 2.92 billion by 2031, at a CAGR of 5.28% during the forecast period (2024-2031).

Some of the major players engaged in the market are Hologic, Inc., GE Healthcare, Siemens Healthineers, Fujifilm Medical Systems, Planmed Oy. Other players include, Metaltronica, Carestream Health, and General Medical Merate. The market is also experiencing the entry of new players, which is expected to intensify competition in the coming years. 'Hologic Inc.', 'GE Healthcare', 'Siemens Healthineers AG', 'Koninklijke Philips N.V.', 'Fujifilm Holdings Corporation', 'Dilon Technologies Inc.', 'Planmed Oy', 'Metaltronica S.p.A.', 'CMR Naviscan Corporation', 'General Medical Merate S.p.A.', 'Delphinus Medical Technologies Inc.', 'Micrima Limited', 'KUB Technologies Inc.', 'Aurora Imaging Technology Inc.', 'Carestream Health Inc.', 'Planmed Oy', 'Zebra Medical Vision Ltd.', 'Volpara Health Technologies Ltd.', 'iCAD Inc.', 'Agfa-Gevaert NV', 'In October 2023, Hologic and Bayer announced a collaborative effort to advance contrast-enhanced mammography (CEM) adoption across Asia Pacific, Canada, and Europe. This pioneering technique involves administering iodinated contrast intravenously and utilizing both low-energy and high-energy X-rays, akin to digital mammography. The iodine selectively absorbs high-energy X-rays, potentially improving cancer detection accuracy. ', 'In October 2023, Syracuse became the hub for cutting-edge breast cancer imaging technology with the installation of two 3-D mammography units at Crouse Hospital. This state-of-the-art technology aims to detect cancerous tumors at earlier stages and enhance cancer detection in denser breast tissue. ', 'In June 2023, Bayer announced that its iodine-based contrast agent, Ultravist (iopromide)-300, -370, received approval from the U.S. Food and Drug Administration (FDA) for contrast-enhanced mammography (CEM). This approval makes Ultravist the only contrast agent authorized for this specific indication. The product is intended for visualizing known or suspected breast lesions in adults, serving as an adjunct to mammography and/or ultrasound. CEM is an emerging imaging modality that combines digital mammography with the administration of a contrast agent like Ultravist to aid in the identification of breast lesions. '

The major factor driving the market growth is rising incidence of breast cancer. Breast cancer is the most common cancer among women worldwide. It is possible to treat breast cancer extremely effectively, especially if the disease is diagnosed early. A breast cancer patient is generally treated with surgery, radiation therapy, and medications (hormone therapy, chemotherapy, and/or targeted biological therapy) to treat the microscopic cancer that has spread from the breast tumor. Treatments such as these can prevent cancer growth and spread, thereby saving lives.

Every year, the incidence of breast cancer in women rises, along with the market expansion and the number of treatments available. Enhanced techniques for breast cancer diagnostics using advanced technologies. More sophisticated technologies for the early detection of breast cancer have improved performance in terms of efficiency, accuracy, efficacy, dependability, and speed of results.

The North America region is anticipated to dominate the contrast enhanced mammography market. The presence of large players, established diagnostic and screening infrastructure, technological breakthroughs, high patient awareness, and reimbursement regulations are the main drivers of this region's dominance.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Contrast Enhanced Mammography Market

Report ID: SQMIG35G2123

$5,300
BUY NOW GET FREE SAMPLE